Difference between PBC & PSC
At the AASLD Liver Meeting 2017, PSC Partners presented this great info graphic that helps explain the differences between PSC Primary Sclerosing Cholangitis and PBC- Primary Biliary Cholangitis. Connect to
MRE Magnetic Resonance Elastography
MRE – Magnetic Resonance Elastography has the ability to accurately assess liver fibrosis without biopsy. Watch this short video to learn more about MRE and how it works.
Researchers link Gut Microbiota to Liver Disease
At the AASLD Liver Meeting in Washington, DC, Dr. Bernd Schnabl presented the 2017 Hans Popper Lecture on Gut Microbiota and Liver Disease. See Dr. Schnabl talk about this on
Now Enrolling Patients in Phase 2 study
Phase 2 trial is now enrolling patients in 50 centers involving 102 patients worldwide. This is a 24 week long study involving 8 clinic visits. Principal Investigators in Canada: Dr.
Currently Enrolling Patients for Phase 2 Study
Currently enrolling patients for Phase 2 Study in Canada, USA, UK and Germany. No placebos will be used, while dosages may differ between participants. Health Canada and FDA approve this
Important Update
Obeticholic acid (Ocaliva) has recently been licenced in Canada for the treatment of people with PBC who have not fully responded to, or who are unable to tolerate, Ursodeoxycholic acid.
Early trials show reduction in liver fibrosis
The American Association for the Study of Liver Diseases published findings that the ASK1 Inhibitor Selonsertib reduced liver fibrosis in stage 2-3 liver fibrosis. In late 2016 Gilead announced that First patients in Canada now taking Ocaliva
After waiting 20 years, this month PBC patients have started on their new treatment option, Ocaliva. For patients who do not respond to ursodeoxycholic acid this has been tremendous news.
New PBC treatment for Itch now in clinical trials in Canada
Itch is common in people with PBC. Currently available treatments are not always effective and may have side effects. In PBC, the bile ducts in the liver become damaged which